[
    {
        "symbol": "INCY",
        "publishedDate": "2020-06-15 11:36:59",
        "title": "Lilly's shares drop as it enrolls first patient in COVID-19 study for arthritis drug",
        "image": "https://images.financialmodelingprep.com/news/lillys-shares-drop-as-it-enrolls-first-patient-in-20200615.jpg",
        "site": "marketwatch.com",
        "text": "Shares of Eli Lilly & Co. undefined were down 1.1% in premarket trading on Monday after the drugmaker said the first patient had been enrolled in a...",
        "url": "https://www.marketwatch.com/story/lillys-shares-drop-as-it-enrolls-first-patient-in-covid-19-study-for-arthritis-drug-2020-06-15"
    },
    {
        "symbol": "INCY",
        "publishedDate": "2020-06-15 11:29:23",
        "title": "Before Spreadsheets, Tape Held Together A Handwritten Chart Discovering The Genetic Code",
        "image": "https://images.financialmodelingprep.com/news/before-spreadsheets-tape-held-together-a-handwritten-chart-discovering-20200615.jpg",
        "site": "khn.org",
        "text": "The chart filled in by biochemists and preserved by the U.S. National Library of Medicine shows how complicated it was to figure out the universal code behind the cells of living organisms.  Other \u2026",
        "url": "https://khn.org/morning-breakout/before-spreadsheets-tape-held-together-a-handwritten-chart-discovering-the-genetic-code/"
    },
    {
        "symbol": "INCY",
        "publishedDate": "2020-06-15 10:46:03",
        "title": "Eli Lilly and : Lilly Begins a Phase 3 Clinical Trial with Baricitinib for Hospitalized COVID-19 Patients | MarketScreener",
        "image": "https://images.financialmodelingprep.com/news/eli-lilly-and-lilly-begins-a-phase-3-clinical-20200615.png",
        "site": "marketscreener.com",
        "text": "",
        "url": "https://www.marketscreener.com/ELI-LILLY-AND-COMPANY-13401/news/Eli-Lilly-and-Lilly-Begins-a-Phase-3-Clinical-Trial-with-Baricitinib-for-Hospitalized-COVID-19-Pat-30771055/"
    },
    {
        "symbol": "INCY",
        "publishedDate": "2020-06-11 00:00:00",
        "title": "Global Leukemia Therapeutics Market Forecast and Opportunities to 2025 - ResearchAndMarkets.com",
        "image": "https://images.financialmodelingprep.com/news/global-leukemia-therapeutics-market-forecast-and-opportunities-to-2025-20200611.jpg",
        "site": "businesswire.com",
        "text": "The",
        "url": "https://www.businesswire.com/news/home/20200611005385/en/Global-Leukemia-Therapeutics-Market-Forecast-Opportunities-2025"
    },
    {
        "symbol": "INCY",
        "publishedDate": "2020-06-10 14:15:38",
        "title": "Small Caps Build Steam And Biotechs Remain Well-Positioned",
        "image": "https://images.financialmodelingprep.com/news/small-caps-build-steam-and-biotechs-remain-wellpositioned-20200610.png",
        "site": "seekingalpha.com",
        "text": "Economic optimism has broadened the market rally. Small caps had lagged significantly and are now catching-up as they narrow the performance gap. The Federal Re",
        "url": "https://seekingalpha.com/article/4353054-small-caps-build-steam-and-biotechs-remain-well-positioned"
    },
    {
        "symbol": "INCY",
        "publishedDate": "2020-06-10 13:20:02",
        "title": "Lonza s'associe les services du su\u00e9dois Cellink dans la bio-impression en 3D | Zone bourse",
        "image": "https://images.financialmodelingprep.com/news/lonza-sassocie-les-services-du-sudois-cellink-dans-la-20200610.png",
        "site": "zonebourse.com",
        "text": "",
        "url": "https://www.zonebourse.com/LONZA-GROUP-2956013/actualite/Lonza-s-associe-les-services-du-suedois-Cellink-dans-la-bio-impression-en-3D-30751551/"
    },
    {
        "symbol": "INCY",
        "publishedDate": "2020-06-10 11:01:00",
        "title": "Here's the Surprising Coronavirus Stock You'll Really Want to Watch Right Now | The Motley Fool",
        "image": "https://images.financialmodelingprep.com/news/heres-the-surprising-coronavirus-stock-youll-really-want-to-20200610.jpg",
        "site": "fool.com",
        "text": "It's a 144-year-old big pharma...but it's quickly become the leader in a key area of fighting COVID-19.",
        "url": "https://www.fool.com/investing/2020/06/10/heres-the-surprising-coronavirus-stock-youll-reall.aspx"
    },
    {
        "symbol": "INCY",
        "publishedDate": "2020-06-09 10:43:50",
        "title": "Ewing Sarcoma Drugs Market 2020 Clinical Survey Report \u2013 Merck, Roche, GlaxoSmithKline, Novartis, Pfizer, Johnson & Johnson",
        "image": "https://images.financialmodelingprep.com/news/ewing-sarcoma-drugs-market-2020-clinical-survey-report-merck-20200609.png",
        "site": "marketwatch.com",
        "text": "Jun 09, 2020 (Market Insight Reports) --\nThe Ewing Sarcoma Drugs Market report is a compilation of first-hand information, qualitative and quantitative...",
        "url": "https://www.marketwatch.com/story/ewing-sarcoma-drugs-market-2020-clinical-survey-report-merck-roche-glaxosmithkline-novartis-pfizer-johnson-johnson-2020-06-09"
    },
    {
        "symbol": "INCY",
        "publishedDate": "2020-06-04 11:31:26",
        "title": "Why Is Incyte (INCY) Up 2.9% Since Last Earnings Report?",
        "image": "https://images.financialmodelingprep.com/news/why-is-incyte-incy-up-29-since-last-earnings-20200604.jpg",
        "site": "zacks.com",
        "text": "Incyte (INCY) reported earnings 30 days ago. What's next for the stock?",
        "url": "https://www.zacks.com/stock/news/963407/why-is-incyte-incy-up-29-since-last-earnings-report"
    },
    {
        "symbol": "INCY",
        "publishedDate": "2020-06-03 17:04:33",
        "title": "Zoom Video Communications\u00a0: Distance et effet de loupe",
        "image": "https://images.financialmodelingprep.com/news/zoom-video-communications-distance-et-effet-de-loupe-20200603.jpg",
        "site": "lesechos.fr",
        "text": "Zoom entretient la flamme de Wall Street pour sa valorisation stratosph\u00e9rique.",
        "url": "https://www.lesechos.fr/idees-debats/crible/zoom-video-communications-distance-et-effet-de-loupe-1208035"
    },
    {
        "symbol": "INCY",
        "publishedDate": "2020-06-02 19:29:45",
        "title": "Eli Lilly (LLY) appears to be on a strong footing with COVID-19 drug development efforts  | AlphaStreet",
        "image": "https://images.financialmodelingprep.com/news/eli-lilly-lly-appears-to-be-on-a-strong-20200602.jpg",
        "site": "news.alphastreet.com",
        "text": "Eli Lilly & Co.'s (NYSE: LLY) shares have gained 29% since the beginning of the year and 16% over the past three months.",
        "url": "https://news.alphastreet.com/eli-lilly-lly-appears-to-be-on-a-strong-footing-with-covid-19-drug-development-efforts/"
    },
    {
        "symbol": "INCY",
        "publishedDate": "2020-07-08 00:00:00",
        "title": "The Daily Biotech Pulse: Intersect ENT Jumps On M&A Speculation, VIVUS Files For Bankruptcy",
        "image": "https://images.financialmodelingprep.com/news/the-daily-biotech-pulse-intersect-ent-jumps-on-ma-20200708.jpg",
        "site": "benzinga.com",
        "text": "Here's a roundup of top developments in the biotech space over the last 24 hours.\nScaling The Peaks\n(Biotech Stocks Hitting 52-week Highs July 7)\n\nAbbVie Inc (NYSE: ABBV)...",
        "url": "https://www.benzinga.com/general/biotech/20/07/16548838/the-daily-biotech-pulse-intersect-ent-jumps-on-m-a-speculation-vivus-files-for-bankruptcy"
    },
    {
        "symbol": "INCY",
        "publishedDate": "2020-07-07 10:00:28",
        "title": "These Red-Hot Biotechs Are Leading The Pack And Could Be Actionable",
        "image": "https://images.financialmodelingprep.com/news/these-redhot-biotechs-are-leading-the-pack-and-could-20201110.jpg",
        "site": "investors.com",
        "text": "The best biotech companies to invest in tend to have a commonality: a strong streak of earnings growth. The post These Red-Hot Biotechs Are Leading The Pack And Could Be Actionable appeared first on Investor's Business Daily.",
        "url": "https://www.investors.com/news/technology/biotech-stocks-best-biotech-companies-to-invest-in/"
    },
    {
        "symbol": "INCY",
        "publishedDate": "2020-07-01 13:33:04",
        "title": "Lonza \u00e9tend ses capacit\u00e9s dans les techniques de particules | Zone bourse",
        "image": "https://images.financialmodelingprep.com/news/lonza-tend-ses-capacits-dans-les-techniques-de-particules-20200701.png",
        "site": "zonebourse.com",
        "text": "",
        "url": "https://www.zonebourse.com/LONZA-GROUP-2956013/actualite/Lonza-etend-ses-capacites-dans-les-techniques-de-particules-30856146/"
    },
    {
        "symbol": "INCY",
        "publishedDate": "2020-08-02 00:00:00",
        "title": "The Week Ahead In Biotech: Novavax Coronavirus Vaccine Readout, FDA Decisions And More Earnings",
        "image": "https://images.financialmodelingprep.com/news/the-week-ahead-in-biotech-novavax-coronavirus-vaccine-readout-20200802.jpg",
        "site": "benzinga.com",
        "text": "Biotech stocks came under pressure in the week ended July 31 amid  mixed earnings  from the sector and some adverse clinical readouts.\nCOVID-19 news flow continued to pour in,...",
        "url": "https://www.benzinga.com/general/biotech/20/08/16888527/the-week-ahead-in-biotech-novavax-coronavirus-vaccine-readout-fda-decisions-and-more-earnings"
    },
    {
        "symbol": "INCY",
        "publishedDate": "2020-08-01 10:34:49",
        "title": "Zurcher Kantonalbank Zurich Cantonalbank Increases Stock Holdings in Incyte Co. (NASDAQ:INCY)",
        "image": "https://images.financialmodelingprep.com/news/zurcher-kantonalbank-zurich-cantonalbank-increases-stock-holdings-in-incyte-20200801.jpg",
        "site": "thelincolnianonline.com",
        "text": "Zurcher Kantonalbank Zurich Cantonalbank lifted its position in Incyte Co. (NASDAQ:INCY) by 10.1% during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 52,991 shares of the biopharmaceutical company\u2019s stock after buying an additional 4,865 shares during the quarter. Zurcher [\u2026]",
        "url": "https://www.thelincolnianonline.com/2020/08/01/zurcher-kantonalbank-zurich-cantonalbank-increases-stock-holdings-in-incyte-co-nasdaqincy.html"
    },
    {
        "symbol": "INCY",
        "publishedDate": "2020-08-01 00:00:00",
        "title": "Xencor Earns Milestone Payment from MorphoSys for FDA Approval of Monjuvi\u00ae (tafasitamab-cxix) in the United States",
        "image": "https://images.financialmodelingprep.com/news/xencor-earns-milestone-payment-from-morphosys-for-fda-approval-20200801.jpg",
        "site": "businesswire.com",
        "text": "Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer and au",
        "url": "https://www.businesswire.com/news/home/20200731005504/en/Xencor-Earns-Milestone-Payment-MorphoSys-FDA-Approval"
    },
    {
        "symbol": "INCY",
        "publishedDate": "2020-09-09 10:05:00",
        "title": "Incyte Announces Recipient of the Inaugural Incyte Ingenuity Award to Recognize Innovative Solutions that Address Needs in the GVHD Community",
        "image": "https://images.financialmodelingprep.com/news/incyte-announces-recipient-of-the-inaugural-incyte-ingenuity-award-20200909.jpg",
        "site": "businesswire.com",
        "text": "WILMINGTON, Del.--(BUSINESS WIRE)--Incyte (Nasdaq:INCY) today announced that Massachusetts General Cancer Center is the recipient of the first Incyte Ingenuity Award, an annual program that was created to support people living with graft-versus-host disease (GVHD) by encouraging innovative and novel solutions that address specific challenges facing the GVHD community.",
        "url": "https://www.businesswire.com/news/home/20200909005229/en/Incyte-Announces-Recipient-Inaugural-Incyte-Ingenuity-Award/"
    },
    {
        "symbol": "INCY",
        "publishedDate": "2020-09-09 07:27:21",
        "title": "Calithera Terminating Partnership, And Other News: The Good, Bad And Ugly Of Biopharma",
        "image": "https://images.financialmodelingprep.com/news/calithera-terminating-partnership-and-other-news-the-good-bad-20200909.png",
        "site": "seekingalpha.com",
        "text": "Calithera signals terminating partnership with Incyte. Lexicon reports dosing in Phase 2 clinical study for LX9211.",
        "url": "https://seekingalpha.com/article/4373211-calithera-terminating-partnership-and-news-good-bad-and-ugly-of-biopharma"
    },
    {
        "symbol": "INCY",
        "publishedDate": "2020-09-03 11:31:28",
        "title": "Incyte (INCY) Down 2.2% Since Last Earnings Report: Can It Rebound?",
        "image": "https://images.financialmodelingprep.com/news/incyte-incy-down-22-since-last-earnings-report-can-20200903.jpg",
        "site": "zacks.com",
        "text": "Incyte (INCY) reported earnings 30 days ago. What's next for the stock?",
        "url": "https://www.zacks.com/stock/news/1052555/incyte-incy-down-22-since-last-earnings-report-can-it-rebound"
    },
    {
        "symbol": "INCY",
        "publishedDate": "2020-09-02 17:04:00",
        "title": "Incyte Announces Pivotal GEOMETRY mono-1 Study Results of Capmatinib (Tabrecta\u2122) in Patients with METex14 Metastatic Non-Small Cell Lung Cancer Published in NEJM",
        "image": "https://images.financialmodelingprep.com/news/incyte-announces-pivotal-geometry-mono1-study-results-of-capmatinib-tabrecta-20200902.jpg",
        "site": "businesswire.com",
        "text": "WILMINGTON, Del.--(BUSINESS WIRE)--Pivotal GEOMETRY mono-1 Study Results of Capmatinib (Tabrecta\u2122) in Patients with METex14 Metastatic Non-Small Cell Lung Cancer Published in NEJM",
        "url": "https://www.businesswire.com/news/home/20200902005825/en/Incyte-Announces-Pivotal-GEOMETRY-mono-1-Study-Results/"
    },
    {
        "symbol": "INCY",
        "publishedDate": "2020-10-08 06:52:12",
        "title": "Kodiak Initiates Phase 3 Trial, And Other News: The Good, Bad And Ugly Of Biopharma (NASDAQ:KOD)",
        "image": "https://images.financialmodelingprep.com/news/kodiak-initiates-phase-3-trial-and-other-news-the-20201008.png",
        "site": "seekingalpha.com",
        "text": "Kodiak Sciences reports initiation of Phase 3 trial of KSI-301. Incyte announces peptide-centric strategic collaboration with Nimble.",
        "url": "https://seekingalpha.com/article/4378092-kodiak-initiates-phase-3-trial-and-news-good-bad-and-ugly-of-biopharma"
    },
    {
        "symbol": "INCY",
        "publishedDate": "2020-10-07 08:06:12",
        "title": "Global Janus Kinase (JAK) Inhibitors Market 2020 includes Vendor Landscape, Research Methodology, Drivers, Challenges and Forecast to 2023 | Absolute Reports",
        "image": "https://images.financialmodelingprep.com/news/global-janus-kinase-jak-inhibitors-market-2020-includes-vendor-20201007.png",
        "site": "marketwatch.com",
        "text": "Oct 07, 2020 (The Expresswire) --\n\"Final Report will add the analysis of the impact of COVID-19 on this industry.\" Global \u201cJanus Kinase (JAK) Inhibitors...",
        "url": "https://www.marketwatch.com/press-release/global-janus-kinase-jak-inhibitors-market-2020-includes-vendor-landscape-research-methodology-drivers-challenges-and-forecast-to-2023-absolute-reports-2020-10-07"
    },
    {
        "symbol": "INCY",
        "publishedDate": "2020-10-06 11:33:10",
        "title": "Zai Lab Announces First Patient Dosed in Greater China in the Global Phase 2/3 MAHOGANY Study of Margetuximab in Gastric and Gastroesophageal Junction Cancer",
        "image": "https://images.financialmodelingprep.com/news/zai-lab-announces-first-patient-dosed-in-greater-china-20201006.png",
        "site": "marketwatch.com",
        "text": "SHANGHAI and SAN FRANCISCO, Oct 06, 2020 (GLOBE NEWSWIRE via COMTEX) --\nSHANGHAI and SAN FRANCISCO, Oct. 06, 2020 (GLOBE NEWSWIRE) -- Zai Lab Limited...",
        "url": "https://www.marketwatch.com/press-release/zai-lab-announces-first-patient-dosed-in-greater-china-in-the-global-phase-23-mahogany-study-of-margetuximab-in-gastric-and-gastroesophageal-junction-cancer-2020-10-06"
    },
    {
        "symbol": "INCY",
        "publishedDate": "2020-10-05 16:48:23",
        "title": "Nimble Announces Strategic Research Collaboration with Incyte to Discover Novel Peptide-Based Therapeutics",
        "image": "https://images.financialmodelingprep.com/news/nimble-announces-strategic-research-collaboration-with-incyte-to-discover-20201005.png",
        "site": "marketwatch.com",
        "text": "Nimble Therapeutics Inc. today announced the company has entered into a strategic collaboration with Incyte (NASDAQ: INCY) to discover first-in-class peptide...",
        "url": "https://www.marketwatch.com/press-release/nimble-announces-strategic-research-collaboration-with-incyte-to-discover-novel-peptide-based-therapeutics-2020-10-05-121594823"
    },
    {
        "symbol": "INCY",
        "publishedDate": "2020-10-05 16:00:21",
        "title": "Nimble Announces Strategic Research Collaboration with Incyte to Discover Novel Peptide-Based Therapeutics",
        "image": "https://images.financialmodelingprep.com/news/nimble-announces-strategic-research-collaboration-with-incyte-to-discover-novel-20201005.png",
        "site": "marketwatch.com",
        "text": "Nimble Therapeutics Inc. today announced the company has entered into a strategic collaboration with Incyte (NASDAQ: INCY) to discover first-in-class peptide...",
        "url": "https://www.marketwatch.com/press-release/nimble-announces-strategic-research-collaboration-with-incyte-to-discover-novel-peptide-based-therapeutics-2020-10-05"
    },
    {
        "symbol": "INCY",
        "publishedDate": "2020-10-05 12:00:00",
        "title": "Nimble Announces Strategic Research Collaboration with Incyte to Discover Novel Peptide-Based Therapeutics",
        "image": "https://images.financialmodelingprep.com/news/nimble-announces-strategic-research-collaboration-with-incyte-to-discover-20201005.jpg",
        "site": "businesswire.com",
        "text": "MADISON, Wis.--(BUSINESS WIRE)--Nimble Therapeutics Inc. today announced the company has entered into a strategic collaboration with Incyte (NASDAQ: INCY) to discover first-in-class peptide therapies across various disease areas. \u201cThis is an important collaboration for both companies to discover novel peptide based therapeutics,\u201d said Jigar Patel, Ph.D., CEO of Nimble Therapeutics. \u201cWe are excited to partner with Incyte, an organization with world-class drug discovery, development and commercia",
        "url": "https://www.businesswire.com/news/home/20201005005184/en/Nimble-Announces-Strategic-Research-Collaboration-with-Incyte-to-Discover-Novel-Peptide-Based-Therapeutics/"
    },
    {
        "symbol": "INCY",
        "publishedDate": "2020-10-04 00:00:00",
        "title": "Three Attractive Health Care Growth Stocks",
        "image": "https://images.financialmodelingprep.com/news/three-attractive-health-care-growth-stocks-20201004.jpg",
        "site": "forbes.com",
        "text": "Healthcare stocks have gained nearly 18.0% in the first nine months of this year, compared to the S&P 500 index\u2019s gain of 3.2% over the same time frame. While the coronavirus pandemic has been disruptive, there are pockets within the healthcare sector that have benefited.",
        "url": "https://www.forbes.com/sites/investor/2020/10/04/three-attractive-health-care-growth-stocks/"
    },
    {
        "symbol": "INCY",
        "publishedDate": "2021-09-01 10:00:51",
        "title": "Should You Buy Incyte Stock Around $75 Levels?",
        "image": "https://images.financialmodelingprep.com/news/should-you-buy-incyte-stock-around-75-levels-20210901.jpg",
        "site": "forbes.com",
        "text": "We believe that the stock price of Incyte, a global biopharmaceutical company, is undervalued at current levels of $75. INCY stock is down 21% over the last-twelve months period, despite revenue increasing 17% over the same period.",
        "url": "https://www.forbes.com/sites/greatspeculations/2021/09/01/should-you-buy-incyte-stock-around-75-levels/"
    }
]